{"links":{"html":"https://www.erudio.com/reports/keynote-b49-nct04895358","json":"https://www.erudio.com/reports/keynote-b49-nct04895358.json","markdown":"https://www.erudio.com/reports/keynote-b49-nct04895358.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"keynote-b49-04895358"}},"request":"https://www.erudio.com/contact?report=keynote-b49-04895358"},"offer":{"cited_commentary_sources":40,"verified_hcp_statements":74,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":23,"optional":true,"price_per_verified_person_usd":15,"price_usd":345,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"keynote-b49-nct04895358"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=keynote-b49-04895358","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/keynote-b49-nct04895358","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T11:17:45.545070Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":21,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":18,"title":"Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1"},{"claim_count":21,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":18,"title":"Secondary endpoints"},{"claim_count":22,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":19,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":8,"coverage":"discussed","id":"A1","source_count":6,"title":"Contemporary alternatives, ADC partners and sequencing"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":5,"title":"Patient burden, cost and individualized value"},{"claim_count":14,"coverage":"discussed","id":"A3","source_count":10,"title":"Biomarker work-up, tissue adequacy and translational research"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":8,"title":"Biological rationale and prior evidence relevant to the metastatic decision"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":2,"title":"Local access and patient-facing treatment discussion"},{"claim_count":10,"coverage":"discussed","id":"A6","source_count":8,"title":"Scientific contribution, reception and limits of consensus inference"}],"counts":{"cited_sources":42,"claims_by_expression_type":{"comparison":4,"experience":1,"interpretation":22,"opinion":19,"primary_context":2,"question":5,"restatement":12,"uncertainty":3,"unspecified":6},"claims_by_kind":{"protocol_statement":1,"publication_statement":1,"source_observation":72},"clinician_statements":27,"evidence_units":73,"findings":8,"organisational_accounts":4,"people_cited":28,"people_identity_verified":23,"people_total":29,"screened_sources":101,"verified_claims":74},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":9},"has_counterview":true,"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":9,"passages":10,"sources":10,"sources_by_kind":{"commentary":10}},"title":"Statistical positivity does not settle the case for broad adoption"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":7},"has_counterview":true,"limitations":4,"links":{"context":1,"support":10},"ma_question":true,"named_voices":7,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Late benefit and higher CPS sustain selective interest, with important evidentiary limits"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Toxicity, administration burden and cost are part of the benefit assessment"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":4},"has_counterview":false,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":4,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"The ADC-era comparator and sequencing question changes perceived relevance"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":8,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"publication":1}},"title":"Better selection is both a biological question and a testing-feasibility problem"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":2,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":3,"passages":8,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"The biological rationale remains contested, with earlier evidence kept separate from metastatic results"},{"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":0,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Conference interest is not equivalent to local treatment availability"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":4,"views":5},"has_counterview":true,"limitations":4,"links":{"context":7,"support":13},"ma_question":false,"named_voices":7,"passages":15,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Scientific value, public reception and consensus are different questions"}],"medical_affairs_question":"Which biomarker-defined patients, if any, have a sufficiently credible durable-benefit signal to justify added toxicity and treatment burden against contemporary alternatives?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Statistical positivity does not settle the case for broad adoption"},{"id":"section-2","level":2,"title":"Late benefit and higher CPS sustain selective interest, with important evidentiary limits"},{"id":"section-3","level":2,"title":"Toxicity, administration burden and cost are part of the benefit assessment"},{"id":"section-4","level":2,"title":"The ADC-era comparator and sequencing question changes perceived relevance"},{"id":"section-5","level":2,"title":"Better selection is both a biological question and a testing-feasibility problem"},{"id":"section-6","level":2,"title":"The biological rationale remains contested, with earlier evidence kept separate from metastatic results"},{"id":"section-7","level":2,"title":"Conference interest is not equivalent to local treatment availability"},{"id":"section-8","level":2,"title":"Scientific value, public reception and consensus are different questions"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T1","label":"Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":8},{"id":"F6","shared_claims":7},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":4}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F8","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T11:17:45.545070Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T11:27:47Z","record_hash":"c8111fb5883cb8445ae96fa42e77849e5e0c86b0bcd4d42ea5d6d7499d64661c","release_hash":"cf3fed2cda20b0f0deaf9ad2a08a6373fbbf6ff537bdc9ef9bf53c6b4256a845","report_id":"erudio-nct04895358","run_id":"f08a06f9-2037-4dd0-bc76-a0390bce4c42","schema_version":"5.0","slug":"keynote-b49-04895358","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on KEYNOTE-B49 in the sources reviewed for this edition leads to one open question: Which biomarker-defined patients, if any, have a sufficiently credible durable-benefit signal to justify added toxicity and treatment burden against contemporary alternatives? Its leading findings: (1) statistical positivity does not settle the case for broad adoption. (2) late benefit and higher CPS sustain selective interest, with important evidentiary limits. (3) toxicity, administration burden and cost are part of the benefit assessment. 5 more findings follow. 101 sources screened, 42 cited; not all HCPs or all public discussion.","meta_description":"101 sources screened · 74 verified statements (27 from clinicians verified by NPI or staff page) from 42 sources · 8 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-31T11:27:47Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":101},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on overall survival, CPS-specific progression-free survival and chemotherapy distribution with pembrolizumab plus chemotherapy.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, quotations and repeated posts cannot be counted as additional independent speakers.","Some passages and organizational commentary were not fully assessed, so additional interpretations or qualifications may be absent.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A full study protocol was not available for assessment, limiting independent evaluation of amendments and planned analyses.","Drug-label review was incomplete, including no exact nab-paclitaxel label. The Japan approval statement applies to October 2026 and cannot establish current or international availability.","The publication excerpt supports methods. Efficacy and safety figures in this report are attributed to the commentators who reported them, not independently reconstructed from results tables.","Higher-CPS observations include small numbers and secondary-endpoint qualifications. CPS greater than ten and CPS ≥10 are preserved as stated, and a speaker's subgroup label rendered as 19 remains uncertain.","Late-tail percentages and terminology differ across authors and have not been harmonized. A speaker's remaining-on wording is not assumed to be a specified PFS rate.","OS maturity is described differently by two speakers. The sources do not justify silently reconciling pending mature OS with final OS.","The interview's three deaths during the study lack arm and causality information and must not be equated with a reported treatment-related fatal-event rate.","Earlier-stage I-SPY 2 evidence, prior metastatic studies and personal treatment experience explain views but are not KEYNOTE-B49 outcomes."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":1,"publication":1,"registry":1,"regulatory":0,"x_thread":35,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":40,"context":1,"methods":1},"count":42,"evidence_window":{"end":"2026-10-30","start":"2023-07-05"},"retrieval_snapshot":"2026-10-31T10:31:42.051638Z","timeline":[{"count":1,"week":"2023-W27"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":31,"week":"2026-W43"},{"count":5,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04895358:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04895358:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42926111","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3mym2xdudn424","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myceoxwtoo2a","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513210439728631808","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519774014513352705","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:484347","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1395334896902545409:a48264c6-7d6a-4a56-8c3b-503eb4eef4fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533382762748514306:ae4a56a2-f450-435e-93f6-bb5e42f1769d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064967760141009039:f2a30661-bcb2-4da1-8b4a-e696946fdbdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102655867090825411:d0f9cae1-c681-4fe6-a8f8-c173bc56b52a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104229388846076194:0d9d7873-8e3e-4019-bdd6-99a0fe5ad858","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104237023829914100:a48a5a77-a2a1-4f64-83b1-19294a10586d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104643429087002850:b8f32652-a38c-4f93-b970-f5ec9dcafc7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106237273075241255:e3a37af1-9bfd-45e8-9bc6-9a19744c816b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107089120774525204:eef35f85-584c-4a96-9165-4d71e1480b5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107911406469501168:7833413a-a524-47d1-9c69-5c28c77f48ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109345852754206978:c7c8ff61-4c18-439d-bd3f-f1ecc331dbbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110661864174584072:593b662b-9e10-4764-b684-fade0d515c74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110663211145982161:dfc92712-9876-45d2-bea2-e969986e636c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110663501437895134:4f1c3460-8348-4179-805c-0b1e6f14e7e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111438871586066579:652acf9c-3ce4-4a54-842a-8841b3e80ee2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111897988188479542:e7ce78e1-27ee-4e9d-a752-b3677f6e2c29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111900164373778720:9eaa18ed-6580-4fc9-ad58-8c4cb8bd231f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112144044583424119:89067670-17dd-4eeb-b513-9f9399ba4d93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112483425747636385:60e9d304-63eb-49f0-905b-2d8883160ef1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112487214869295477:2096cbb5-3703-480e-9e38-daeb65addd2f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112878415535890666:6809ef63-faf7-423b-aab3-e7a379f92f2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113016006079889625:b9af0187-92ca-4df3-953d-aa06054ef369","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113374841621360785:d26372f1-8e4e-4bbd-be69-22589218e36c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113645626760348023:572073cf-bf0e-437c-8972-31fd97f0bc92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113759132595470340:954d5edf-8e0e-446c-a60f-4d252941e12f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113871578865782996:a55926b7-6ee3-4365-b3a9-118ebf9a3d19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113879259706282102:f2b85766-37f7-4888-a054-82278915394d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113880670082838777:bb8a090f-9462-4278-92bc-49a16003419c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113880715762741474:ac1e8b09-69cb-4779-aa32-4069f4ec8613","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113883375383773313:9f3ff414-a6a6-47c6-9ab8-c8bbba2bc83b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113883433760100850:c54f2cd8-9b77-4b3d-a538-db8d4d89411f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113883838149529903:c658d6e1-02e7-4390-bc20-6ba6d7d09219","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113883850292048320:559f4fa0-b152-4c87-81f2-c1b78c9f3faa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113883940436279532:2877f758-ca35-4c9d-8542-b1313723593a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884154366693433:30a3d8c2-0065-4637-b440-44797f2cb5b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884281671909603:ed04391b-d66e-4f2e-a2ac-80f8d5a02082","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884334910542245:2fa47faf-7b83-4d65-92ee-c5a8feceae42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884420134301808:2d5d32cc-7eb0-461f-a3a3-fa241c035848","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884612657021047:035ffe27-9aeb-4b84-89c2-e77db6111097","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884666088284473:ba5f31ee-2e54-4a4f-a118-902521a2eda7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113884861853487129:4d756403-749c-4265-b57b-699d0b439d9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113885257137262871:cfb5280b-d7ae-4198-9d29-fcb5bba0d855","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113885370056356035:e92338c8-f6a8-4412-8074-5ef4b7ee2298","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113885577401790885:e90f2422-01af-4e62-ac5f-ee7ee2f79c86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113886173982773303:ad012d18-7b4c-4fdb-a5d2-75be675f1603","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113886223035179376:db110205-eec3-4a3c-8c06-997e36ff7b5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113886282900500642:3fd53ee5-3092-4c43-990c-8e6e2ef57b08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113886349698662615:0b7bc5a6-a7fb-4fbd-bde3-5d18cd3994a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113886745150263341:1a6553b9-af65-4c76-ac9d-e4c775d44511","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113889493941903715:623ce47c-37db-417c-a640-03cefddcaceb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113892065390002338:2f086a21-db02-4d2c-8324-cd55ab8073e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113892313403384211:6d9e4819-e18f-42a3-848a-47f691ea734e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113892798109983113:b858d561-6bf0-445f-8a45-d5e9a814d8c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113894021039104454:30b828d6-0881-41d7-ac0c-8dd8c5583b83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113900028502982802:ccadc341-6986-4c07-a385-84fc1a21b0ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113900262414762060:20cb5c40-4906-4dcf-85db-f3e41124d806","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113901814475325611:f28c01b6-dc52-4b66-a7c7-917104fdce26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113914119111733366:a6fcfabd-7dd3-4f49-85d7-48367cc9535b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113916444391911789:842e933e-8302-477a-896d-a0fd7ad9b4fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113919609204068400:1b62bfc7-57cf-49a5-ac30-f91df2bbc07d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113927185769611606:64f096e0-bf47-46f1-976d-10496216a797","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113976992513036429:ef87b6a8-9ad4-401d-aec5-2b3550da34df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113977098629001312:f5661f3a-4ec9-4c99-81a6-5b2932ccd70b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114003003464421497:5f287883-94ec-4e6f-a2ca-ad7326afba8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114010839493779757:50e97c81-8122-44fb-a7c0-69f36429dddc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114033771771212096:5b36db65-2f45-4e64-b075-7139d491a106","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114217700410937633:61551929-edc0-4cc7-85bb-5a89326c009b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114243289448648725:c3d877b9-80ca-4977-a393-e37a0eba448b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114244076174242092:57100e31-b20c-4277-b48b-22fb14a534d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114252445018955890:ec1eacbe-0c65-41e3-b6ca-f40889dac0f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114254574743605475:fe010609-ba8e-48bb-9974-770344a1bce7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114255001740882329:0f61b031-4e12-4707-a66c-f0ef047deb55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114255157026234579:5ae642e0-0220-4032-bf0a-e5b94bb009e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114296889529004200:9f4a203b-42e5-4eac-a760-7e841894382d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114311847734124743:1a3f8d26-0ed0-420d-853d-4116c07a1bb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114334017256374287:0f6ec357-8806-4a0b-83ac-abdbdcc53834","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114538788907016378:a7a35e9d-2ae5-47a9-bd92-6a5aea8f1ac1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114673878467334208:784fb13a-86f4-49df-b2f0-adef1afadf77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114735573998960783:405211a8-8aed-4fba-8c6c-af5421bd0a7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114741961009574066:c646f0bd-20de-4529-9c61-72a43a84fce5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115077491194737128:d59e0fa4-977a-4b8d-b3a7-edd04993b59a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115150744655475107:52a690d5-d275-4976-bc5a-b44238ae4ac6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115421448739385544:b80b3f32-58fb-493f-886d-890efaf0c78e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115437911860519385:7b99af74-3611-4541-9e9a-766c0c791548","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115460025527259217:e481ce98-2d77-494a-b01d-756559f7cf2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115739401129218076:0ecb3510-750b-4ea6-8dc3-da317d1fdf94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115780429508677880:219951c8-b417-4c85-a573-7a6734c98b81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115851818484031687:6b5aa29b-ec4c-4d9c-a831-f6738cf357c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115857678723395858:0a8b1811-7c32-47cb-ad2e-b62eb394d52f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115880228992004511:d93d724c-6843-44e1-8558-802cd5e63fe4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116198550665310642:0b3c5618-5132-4712-91f0-20536de426c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116237990611787800:976f1236-c4f9-43d5-8b4e-d48393ed12de","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YfTsa2lCfyI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:alZvkdAQbPc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uqZD1RCbQMs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xrFGHEG0gXs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":92,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":101},"count":101,"evidence_window":{"end":"2026-10-30","start":"2021-05-20"},"retrieval_snapshot":"2026-10-31T10:31:42.520276Z","timeline":[{"count":1,"week":"2021-W20"},{"count":1,"week":"2022-W22"},{"count":1,"week":"2023-W21"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2026-W24"},{"count":3,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":4,"week":"2026-W41"},{"count":7,"week":"2026-W42"},{"count":63,"week":"2026-W43"},{"count":17,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"reason":"Unmapped registry intervention: liposomal doxorubicin","status":"unmapped"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"},{"reason":"Unmapped registry intervention: normal saline","status":"unmapped"},{"reason":"Unmapped registry intervention: dextrose","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Breast Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"KEYNOTE-B49","aliases":["KEYNOTE-B49","MK-3475-B49/KEYNOTE-B49","Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)"],"brief_title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Breast Neoplasms"],"display_condition":"HR+/HER2- locally recurrent inoperable or metastatic breast cancer","display_interventions":[["pembrolizumab"]],"enrollment":{"count":342,"type":"ACTUAL"},"interventions":[{"name":"pembrolizumab","synonyms":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"paclitaxel","synonyms":["TAXOL®"],"type":"DRUG"},{"name":"nab-paclitaxel","synonyms":["ABRAXANE®"],"type":"DRUG"},{"name":"liposomal doxorubicin","synonyms":["DOXIL®"],"type":"DRUG"},{"name":"capecitabine","synonyms":["XELODA®"],"type":"DRUG"},{"name":"normal saline","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"dextrose","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04895358","official_title":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-04-24","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS in participants with a CPS of ≥1, as assessed by BICR, will be presented.","measure":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1","timeFrame":"Up to approximately 50 months"}],"registered_date":{"date":"2021-05-20","type":"ACTUAL"},"registry_last_updated":"2026-07-22","registry_url":"https://clinicaltrials.gov/study/NCT04895358","short_name":"KEYNOTE-B49","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2021-06-18","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"3475-B49","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-3475-B49","type":"other"},{"domain":"MSD","id":"KEYNOTE-B49","type":"other"},{"domain":"EU CT","id":"2023-506752-24-00","type":"registry"},{"domain":"UTN","id":"U1111-1294-3354","type":"registry"},{"domain":"Japan Registry of Clinical Trials (jRCT)","id":"jRCT2051210049","type":"registry"},{"domain":"Philippine Health Research Registry (PHRR)","id":"PHRR210721-003751","type":"registry"},{"id":"2020-005407-38","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}